11:40 AM EDT, 03/12/2026 (MT Newswires) -- Aptiv ( APTV ) could move higher after its planned April 1 spin-off of Versigent, as there is room for the remaining Aptiv ( APTV ) business to trade at a higher valuation, UBS said in a note Thursday.

Even if Versigent trades at 4.5 times 2027 enterprise value to earnings before interest, taxes, depreciation, and amortization, the market would still be valuing the remaining Aptiv ( APTV ) business at about $56 a share, which UBS sees as too low.

UBS's sum of the parts analysis suggests investors buying Aptiv ( APTV ) at current levels are getting Versigent at no added cost, according to the note.

Versigent is worth about $17 a share within the current Aptiv ( APTV ) and about $51 a share as a standalone company, with a fair value range of $44 to $58 a share, the investment firm said.

UBS upgraded Aptiv ( APTV ) to buy from neutral and raised its price target to $97 from $89.

Price: 70.59, Change: +0.27, Percent Change: +0.38